| Madrid | |
| 0 | |
| Oryzon is a clinical stage biopharmaceutical company developing innovative epigenetic-based therapies in oncology and neurodegenerative diseases. The company has one of the strongest portfolios in the field and a clinical asset already partnered with ROCHE. | |
| Program ORY-1001: LSD1 has been associated as a target for the treatment of hematological cancers like acute leukemia and myelodisplastic syndrome, solid tumors such as Small Cell Lung Cancer and others, and in other hematological non-malignant diseases such as Sickle cell disease. ORY-1001 is an exquisitely selective and potent LSD1 inhibitor, which can be orally administered to patients. This compound is currently in a Phase I/IIA clinical trial for acute leukemia (AL) and the first part of the study has finalized with the determination of the MRD and the preliminary assessment of a good safety profile and characterization of PK, PD and target engagement. Program ORY-2001:ORY-2001 is an epigenetic modulator for the treatment of Alzheimers disease and other neurodegenerative disorders. ORY-2001 is a small molecule with potent and highly selective dual LSD1-MAOB inhibition, the drug has an excellent PK profile allowing a once a day oral administration and crosses the BBB.A Clinical Trial Application has been filed with the Spanish Drug Agency (AEMPS) to conduct a Phase I clinical study with healthy volunteers as a first step to determine the potential of ORY-2001 for the treatment of Alzheimers disease. |
|
| BARAN Anna | |
| www.oryzon.com | |
| N/A |
Fiche créée le 10/04/2016 par 
Guillaume vue 23 fois.